Campbell Prostate Cancer Flashcards
Prostate cancer has been the most common _____ in US men since 1984, now accounting for 19% of all such cancers.
Prostate cancer incidence varies by race/ethnicity, with _____ experiencing a 73% higher incidence rate than whites
noncutaneous malignancy
African-Americans
_______ have the highest incidence of prostate cancer in the world, although incidence rates have been decreasing at a similar rate to Caucasians, at least in part resulting from a recent decrease in PSA testing
African-Americans and Jamaicans of African descent
Prostate cancer is the _____ most common cancer and the _____leading cause of cancer deaths worldwide, with an estimated 1.1 million new cases and 300,000 deaths in 2012
2nd most common
5th leading cause of cancer death
In the Prostate Cancer Prevention Trial (PCPT), ____ of men in the placebo arm were diagnosed by annual PSA screening within ___ years of enrollment suggesting that lifetime risk for regular screening may approach ____
14% within 7 years of enrollment
Lifetime risk: 20%
The rationale for finasteride (a selective type 2 5α-reductase inhibitor [5ARI]) as a chemopreventive agent was based on ______
the absence of prostate cancer in men with congenital deficiency of 5α-reductase (the enzyme that converts T to DHT) and the critical role of androgens in the development of prostate cancer.
The main finding of PCPT was a ______ reduction in the period prevalence of prostate cancer in men taking finasteride (18.4%) compared with placebo (24.4%)
25% reduction in period prevalence
However, a significant increase in the prevalence of _______ in men receiving finasteride (280 [37%]) compared with placebo (237 [22%]),
biopsy Gleason score 7 to 10 cancers was observed
particularly for biopsy Gleason score 8 to 10 cancers (90 [12%] in the finasteride arm vs. 53 [5%] in the placebo arm).
Another observation:
Marked effect of finasteride on the prevalence of biopsy _____ , no effect on the prevalence of biopsy ______, and an increase in the prevalence of biopsy _______
Gleason score 2 to 6 tumors - marked effect
Gleason score 7 tumors - no effect
Gleason score 8 to 10 tumors - increase
Secondary analyses of PCPT have demonstrated an overall _______ for the diagnosis of prostate cancer in the finasteride arm.
Finasteride-treated glands were also _______ on average compared with those in the placebo arm, and data suggest that having a smaller prostate ENHANCES the detection of cancer, and proportionately more diagnosed cancers are high-grade
improved sensitivity of DRE, and a higher accuracy of PSA
28% smaller
Does finasteride cause development of high-grade PCa?
NO. There appeared to be no morphologic effect of finasteride on prostate cancer grading when specimens were reviewed by a panel of expert pathologists blinded to the treatment arm
** rate of upgrading from biopsy Gleason score 2 to 6 to pathologic Gleason score 7 to 10 among men treated by radical prostatectomy was higher in the placebo arm compared with the finasteride arm
Dutasteride reduced the risk for ______ over 4 years by 23% (858 in the placebo arm vs. 659 in the dutasteride arm, P < 0.001) and showed similar reductions in years 1 to 2 and years 3 to 4
prostate cancer
The PCPT and REDUCE trials confirm the consistency of effect of ____ at reducing the _____ with a similar magnitude of risk reduction across all subgroups.
5ARIs
risk for prostate cancer,
Toremifene citrate: Does it reduce prostate Ca risk?
A randomized trial in 1467 men with HGPIN FAILED to show a reduction in prostate cancer incidence at 3 years among those receiving tore- mifene citrate 20 mg daily vs. placebo, even among select high-risk groups
Organizations such as the AUA recommend shared decision making for men _____ considering PSA-based screening, a target age group for whom benefits may outweigh harms
55 to 69 years of age
PRE-BIOPSY: After an FDA warning and label change in 2016 regarding fluoroquinolone toxicity (musculoskeletal concerns [tendinitis and tendon rupture], peripheral neuropathy, central nervous system side effects, or myasthenia gravis), the AUA recommended shortening the use of _____ prophylaxis to a ____
fluoroquinolone
maximum of 24 hours.